Detalles de la búsqueda
1.
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN.
Am Heart J
; 274: 32-45, 2024 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38705341
2.
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
N Engl J Med
; 382(16): 1520-1530, 2020 04 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-32197277
3.
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
Lipids Health Dis
; 14: 98, 2015 Sep 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-26328624
4.
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial.
J Clin Lipidol
; 17(4): 491-503, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37277261
5.
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial.
Nat Med
; 28(8): 1672-1678, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35953719
6.
Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
Vasc Health Risk Manag
; 9: 563-73, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24124374
7.
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
Clin Ther
; 35(9): 1400-11.e1-3, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23998969
Resultados
1 -
7
de 7
1
Próxima >
>>